The study reviewed US medical claims databases from 2005 to 2021 and compared CVD outcomes in narcolepsy patients and ...

The link between narcolepsy and cardiovascular disease (CVD) was strengthened by new evidence that the relationship applied to subclinical disease and was apparent early in life, based on a ...

At week 1, AXS-12 reduced cataplexy attacks by 56%, compared to 31% with placebo, in patients with narcolepsy. The experimental treatment, AXS-12 (reboxetine), compared with placebo, significantly ...

Patients included N=22 293 diagnosed with narcolepsy (NT1 and NT2) and N=63 709 propensity‐score–matched without. Patients with narcolepsy were identified as those with ≥2 outpatient insurance claims ...

The tetrad of features for Type 1 narcolepsy are: excessive sleepiness, sleep paralysis, sleep related hallucinations, and cataplexy. Type 2 is similar but without cataplexy. Consider narcolepsy in ...

A 2021 review of past research suggests that 45.6% more people with narcolepsy have OSA than those without narcolepsy ... people who have narcolepsy with cataplexy. Night eating syndrome was ...

SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed.

Without being properly diagnosed and treated ... For years, Jazz Pharmaceuticals has dominated the market in treating narcolepsy with cataplexy. But increased competition is on the horizon.